The animosity between pharmaceutical companies and PBMs runs deep, fueled by diverging interests and conflicting objectives. While PBMs are crucial in managing drug benefits and containing costs, their opaque pricing practices and market dominance have drawn the ire of pharmaceutical CEOs. By seekin...